Drugs / ALVAC-RG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000884 | ? → Oct 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001055 | ? → Nov 1997 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00007423 | ? → Sep 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-RG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001055 ↗ |
| Known as | vCP65 | “ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00007423 ↗2“ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00000884 ↗ “ALVAC-RG Rabies Glycoprotein (vCP65)” NCT00001055 ↗ |
| Modality | Vaccine | “control therapy with ALVAC-RG vCP2058 (rabies vaccine)” NCT00000884 ↗ |
| Route | Intramuscular | “Participants will undergo treatment intramuscularly” NCT00000884 ↗ |